BFG
CORT icon

Bleakley Financial Group’s Corcept Therapeutics CORT Stock Holding History

Bleakley Financial Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
+11,638
New +$703K 0.01% 650
2025
Q2 		– Sell
-16,453
Closed -$1.88M – 577
2025
Q1 		$1.88M Buy
+16,453
New +$1M 0.06% 251

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bleakley Financial Group's CORT Position: Q2 2026 in Review

Bleakley Financial Group opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 11,638 shares worth $1.01M. The stake represents 0.01% of the portfolio and ranks #650 among its holdings. This is a return to the name: Bleakley Financial Group previously reported a position in CORT as recently as Q1 2025.

Bleakley Financial Group first reported a position in CORT in Q1 2025 and has held it in 2 quarters since. The position peaked at $1.88M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Bleakley Financial Group held 11,638 shares of Corcept Therapeutics worth $1.01M as of Q2 2026.
  • Corcept Therapeutics was a new Bleakley Financial Group position in Q2 2026.
  • Corcept Therapeutics made up 0.01% of Bleakley Financial Group's portfolio in Q2 2026, its #650 holding.
  • Bleakley Financial Group first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Bleakley Financial Group's Corcept Therapeutics position peaked at $1.88M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Bleakley Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.